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222Large Left Ventricular Thrombus as a Cause
of Recurrent Cardioembolic Stroke While
on Dabigatran
Melissa Y. Y. Moey, MD, MSc, Anna N. Tomdio, MD, Olisaemeka Achike, MD,
and Deepa Kabirdas, MD, Greenville, North CarolinaINTRODUCTION
Cardioembolic stroke (CES) is responsible for an increasing number
of ischemic strokes. Half of the cases are often secondary to nonvalv-
ular atrial fibrillation, while another 10% are due tomural thrombus in
the atrium or ventricle.1 In comparison with other subtypes of
ischemic stroke, studies have shown that CES cause more severe
devastating effects because of the increased likelihood of compromise
of a larger area of the brain.1 Thrombus formation can develop in the
atrium secondary to atrial fibrillation, while clot formation in the left
ventricle occurs mostly following myocardial infarction (MI) of the
anterior wall because of blood stasis from a dysfunctional left
ventricle.2 In patients who have had ischemic stroke with left ventric-
ular (LV) thrombus as an identifiable cause, guidelines issued by the
American College of Cardiology recommend the use of oral vitamin
K antagonists (VKAs) as primary anticoagulant therapy.3 Although
there has been some evidence for the use of direct oral anticoagulants
(DOACs) for LV thrombus in case reports, there have been no ran-
domized studies to demonstrate its role in large clot burden, appro-
priate therapeutic dosing, and effective duration. We report a case
of a young man with a history of a significant LV thrombus burden
who had recurrent large cardioembolic ischemic stroke while on da-
bigatran.CASE PRESENTATION
A39-year-old African Americanman presented with a syncopal event
and subsequently developed myoclonic activity concerning for
seizure, for which he was loaded with fosphenytoin and treated
with lorazepam. Head computed tomography demonstrated an acute
right parietal cerebrovascular accident with progressive cerebral
edema. Due to increased somnolence, he required intubation.
His medical history was significant for type 2 diabetes mellitus,
hypertension, anterior MI with stent placement to the left anterior
descending coronary artery in 2006, and chronic total occlusion of
the left anterior descending coronary artery in 2015. He also had a pre-f Internal Medicine (M.Y.Y.M., A.N.T.) and the Department
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/j.case.2018.04.008vious left middle cerebral artery ischemic stroke in 2011 with residual
moderate to severe expressive aphasia and right-sided weakness, for
which he was on anticoagulation with dabigatran. The etiology of
his first stroke was considered to be cardioembolic, for which warfarin
was initiated, but because of noncompliance, the patient was switched
to dabigatran.
He was admitted to the medical intensive care unit because of
initial concerns of seizure-like activity in the setting of a new acute
ischemic stroke. Cardiovascular examination was negative for mur-
murs, rubs, or gallops. No peripheral edema was noted. Laboratory
data showed normal platelet count, white blood cell count, hemoglo-
bin, and hematocrit. Hypercoagulable studies including factor II, factor
V, protein C, protein S, lupus anticoagulant, anti–deoxyribonucleic
acid antibody (Ab), ribonucleic protein Ab, anti-SSA/SSB Ab, and
anti-Smith Ab were all negative. Hemoglobin electrophoresis per-
formed showed an elevation of hemoglobin A2 suggestive of b-thalas-
semia minor. Transthoracic echocardiography revealed LV ejection
fraction of 25% and segmental wall motion abnormalities in LAD dis-
tribution. A large, pedunculated mobile elongated hyperechoic mass
measuring 5.6 cm in length and 3.4 cm in width was visualized
attached to the LV apex with a narrow stalk (Figure 1, Videos 1-7).
Given its of size and mobility, there was concern for thrombus
dislodgement and embolization. He was placed on a heparin drip,
and both cardiology and cardiothoracic surgery were consulted given
the likely ischemic nature of his cardiomyopathy and large LV
thrombus. Left heart catheterization and coronary angiography
showed total occlusion of the proximal portion of the LAD
(Figure 2). Following stabilization of neurologic status, the patient un-
derwent excision of the LV mass. Intraoperative findings included
heavy calcification of the LV apex, distal septum, and distal anterior
wall. Pathology confirmed a nonmalignant mass and findings consis-
tent with a thrombus.
Due to concern formedication noncompliance and social issues, he
was not considered an ideal candidate for warfarin. Hewas discharged
home on DOAC therapy. Follow-up echocardiography 1 month and
2 years after thrombectomy showed no evidence of LV thrombus
(Figure 3) on DOAC therapy. He declined the recommendation of
an implantable cardioverter-defibrillator for persistent LV dysfunction
despite optimal medical therapy. He continues to be followed as an
outpatient in the cardiology clinic.DISCUSSION
LV mural thrombi account for up to 10% of CES and are most often
seen in patients who have had extensive anterior MIs. Regional wall
motion abnormality resulting in blood stasis, endocardial injury with
associated inflammatory changes, and hypercoagulable state all
contribute to thrombus formation in the setting of acute MI. In addi-
tion to anterior MI, other risk factors for the development of LV
thrombus include large infarct size, severe apical asynergy (i.e.,
Figure 1 Transthoracic echocardiogram demonstrating left ventricular thrombus observed in the parasternal (A) short- and (B) long-
axis views. Thrombus dimensions seen in both views are measured as 2.48 x 3.47 x 5.33 cm. Ao, Aorta; LA, left atrium; LV, left
ventricle; RVOT, right ventricular outflow tract.
Figure 2 Left heart catheterization and coronary angiogram
demonstrating total occlusion of the proximal portion of the
LAD with trace antegrade filling.
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Moey et al 223akinesis or dyskinesis), and LV aneurysm.4 The timeline for develop-
ment of a thrombus after MI varies between 24 hours and 2 weeks,
with an increased risk in patients with worsening LV function.2 In
the absence of anticoagulation, 3-month embolism risk with an LV
thrombus is as high as 10%–20%, with the highest risk during the first
1–2 weeks.3,5 Risk for embolization diminishes after 3 months
because of organized fibrotic clot adhering to the endocardium.
With therapy, patients with apical akinesia seem to have more rapid
resolution compared with those with apical aneurysm or dyskinesia.5
The current American College of Cardiology guidelines recom-
mend oral VKA for 3 months in patients with asymptomatic LV
thrombus (class IIa). Themain goal of anticoagulation is to prevent sys-
temic embolization and stroke. In patients who require concurrent
dual-antiplatelet therapy, such as those who undergo percutaneous
coronary intervention with stent placement, a lower international
normalized ratio goal of 2.0–2.5 is recommended because of the
increased risk for bleeding (class IIb).2,3 In comparison, the
European Society of Cardiology recommends treatment with a
VKA for up to 6 months, guided by repeat echocardiography, and
consideration for concomitant DAPT and bleeding risk.6Dabigatran is a direct competitive inhibitor of thrombin. There are
no studies comparing the effectiveness of dabigatran versus warfarin
in patients with LV thrombus, but there have been studies evaluating
hemorrhagic risk. In the Randomized Evaluation of Long-Term
Anticoagulation Therapy trial,7 rates of hemorrhagic stroke were
found to be significantly reduced in the group receiving dabigatran
(150 mg) than in those receiving warfarin (0.10% vs 0.38%, respec-
tively; relative risk, 0.26; 95% CI, 0.14–0.49; P < .001). Despite these
findings, the utility of DOAC therapy for the treatment of LV
thrombus has not been fully elucidated. The majority of the evidence
that support use of DOAC therapy originate from case reports,8-11 but
there are no randomized studies or case reports involving large and
mobile clots. The use of apixaban,8 rivaroxaban,9 and dabigatran10
has been cited in a few case reports of LV thrombus resolution, but
notably, the majority of the clot burden was <2 cm in size.
Our patient did have a history of nonadherence to therapy and re-
ported missing <1 week of his medication. Although it is possible for
mural thrombus to develop within this time frame, it is questionable
that a massive thrombus of the size observed could develop within a
short span of time. It is likely that he had pre-existing thrombus burden
that increased rapidly following interruption of therapy rather than de
novo thrombus formation. Studies both in vitro and in vivo have shown
that in contrast to factor Xa inhibitors, direct thrombin inhibitors such as
dabigatran in lower doses tend to have a potential paradoxical effect by
increasing thrombin generation via suppression of thenegative feedback
system.11Mechanical prosthetic valve thrombosis ondabigatran therapy
has been reported in the literature, and it has been proposed that local
generation of thrombin via intrinsic pathway in mechanical heart valves
tends to overwhelm conventional doses of dabigatran.12 This brings into
question the efficacy of DOACs in management of existing thrombus
burden. In addition, Vene et al.,13 on the basis of registry data, showed
that interruption of DOAC therapy increased short-term thromboem-
bolic risk by >20-fold, typically in the first month. In a recent case report
by Bachvarova et al.,14 disruption of dabigatran in addition to inadequate
dosingwas shown tohavepotentially contributed to thedevelopment of
two large thrombi in the left atrium. We believe that a combination of
factors unique todirect thrombin inhibitors describedabove, such aspar-
adoxical thrombus generation, possible decreased efficacy in the setting
of existing thrombus burden, and rebound hypercoagulability following
discontinuation, all likely contributed to the massive thrombus rather
than nonadherence to therapy alone given the brief period of interrup-
tion.Althoughmanypotential explanations exist as to themechanismof
massive mural thrombus in our patient, it raises several important ques-
tions not onlywith respect to the role ofDOAC therapy inmanagement
of existing LVmural thrombus but also appropriate dosing and bridging
Figure 3 Transthoracic echocardiogram parasternal long-axis views (A) one month and (B) two years after thrombectomy with no
evidence of thrombus. Ao, Aorta; LA, left atrium; LV, left ventricle; RVOT, right ventricular outflow tract.
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studies targeted to answer these specific issues are crucial.
There are currently no statements outlining the appropriateness of
anticoagulation in large thrombus burden. A study measuring the
long-term outcomes of anticoagulation versus surgical resection of
LV thrombi was conducted, and the risk for systemic thromboembo-
lism was higher in the former at 17.7% compared with 0% in the
latter.15 In another meta-analysis by Vaitkus and Barnathan,3 there
was a reduction in incidence of LV thrombus if thrombolytic therapy
was used, but this did not achieve statistical significance. In our patient,
who had significant LV thrombus burden and a history of noncompli-
ance, surgical thrombectomy as first-line therapy followed by a
DOAC may have produced a better outcome. As such, for future
consideration, the utility of DOAC therapy in LV thrombus may be
recommended for LV thrombus size of <2 cm. Additional studies of
its use in large LV thrombi are further warranted.
CONCLUSION
LV mural thrombi have significant morbidity and potential mortality
because of risk for systemic embolization and ischemic stroke.
Anticoagulation with oral VKA therapy for a duration of 3 months
is the recommended treatment of choice in patients with LV mural
thrombus. DOAC therapy is considered second-line and is reserved
for patients who are intolerant to VKA therapy, as there are no
large-scale randomized studies to date demonstrating long-term out-
comes. The majority of current use of DOAC therapy in LV thrombus
originates from observational case reports, with no data to support use
for large thrombus size. Our report of a patient with a large LV
thrombus and recurrent stroke while on dabigatran highlights the
important question of the utility of DOAC therapy in patients with
large LV thrombi and need for further studies.SUPPLEMENTARY DATA
Supplementary data related to this article can be found at https://doi.
org/10.1016/j.case.2018.04.008.REFERENCES
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